SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Molina Healthcare, Inc. – ‘10-Q’ for 6/30/20 – ‘R10’

On:  Friday, 7/31/20, at 10:00am ET   ·   For:  6/30/20   ·   Accession #:  1179929-20-111   ·   File #:  1-31719

Previous ‘10-Q’:  ‘10-Q’ on 5/1/20 for 3/31/20   ·   Next:  ‘10-Q’ on 10/29/20 for 9/30/20   ·   Latest:  ‘10-Q’ on 4/25/24 for 3/31/24

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 7/31/20  Molina Healthcare, Inc.           10-Q        6/30/20   65:8.9M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    896K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     23K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     23K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     20K 
12: R1          Cover Page                                          HTML     71K 
13: R2          Consolidated Statements of Income                   HTML     92K 
14: R3          Consolidated Statements of Comprehensive Income     HTML     41K 
15: R4          Consolidated Balance Sheets                         HTML     99K 
16: R5          Consolidated Balance Sheets (Parenthetical)         HTML     33K 
17: R6          Consolidated Statements of Stockholders' Equity     HTML     80K 
18: R7          Consolidated Statements of Cash Flows               HTML    115K 
19: R8          Organization and Basis of Presentation              HTML     35K 
20: R9          Significant Accounting Policies                     HTML    116K 
21: R10         Net Income per Share                                HTML     64K 
22: R11         Fair Value Measurements                             HTML    146K 
23: R12         Investments                                         HTML    158K 
24: R13         Medical Claims and Benefits Payable                 HTML     54K 
25: R14         Debt                                                HTML     51K 
26: R15         Stockholders' Equity                                HTML     59K 
27: R16         Segments                                            HTML     75K 
28: R17         Commitments and Contingencies                       HTML     23K 
29: R18         Significant Accounting Policies (Policies)          HTML     98K 
30: R19         Significant Accounting Policies (Tables)            HTML    107K 
31: R20         Net Income per Share (Tables)                       HTML     64K 
32: R21         Fair Value Measurements (Tables)                    HTML    147K 
33: R22         Investments (Tables)                                HTML    157K 
34: R23         Medical Claims and Benefits Payable (Tables)        HTML     55K 
35: R24         Debt (Tables)                                       HTML     44K 
36: R25         Stockholders' Equity (Tables)                       HTML     54K 
37: R26         Segments (Tables)                                   HTML     71K 
38: R27         Organization and Basis of Presentation (Details)    HTML     48K 
39: R28         Significant Accounting Policies - Cash and Cash     HTML     28K 
                Equivalents (Details)                                            
40: R29         Significant Accounting Policies - Narrative         HTML     47K 
                (Details)                                                        
41: R30         Significant Accounting Policies - Amounts Due To    HTML     38K 
                Government Agencies (Details)                                    
42: R31         Significant Accounting Policies - Quality           HTML     37K 
                Incentive Premium Revenue Recognized (Details)                   
43: R32         Significant Accounting Policies - Receivables       HTML     31K 
                (Details)                                                        
44: R33         Net Income per Share (Details)                      HTML     63K 
45: R34         Fair Value Measurements - Fair Value of Financial   HTML     97K 
                Instruments on Recurring Basis (Details)                         
46: R35         Fair Value Measurements - Balance Sheet Grouping    HTML     30K 
                (Details)                                                        
47: R36         Fair Value Measurements - Details of Long-Term      HTML     70K 
                Debt (Details)                                                   
48: R37         Investments - Summary of Investments (Details)      HTML     54K 
49: R38         Investments - Contractual Maturities of             HTML     47K 
                Available-for-Sale Investments (Details)                         
50: R39         Investments - Narrative (Details)                   HTML     28K 
51: R40         Investments - Available-for-Sale Investments        HTML     49K 
                (Details)                                                        
52: R41         Medical Claims and Benefits Payable - Medical       HTML     28K 
                Claims and Benefits Payable (Details)                            
53: R42         Medical Claims and Benefits Payable - Narrative     HTML     22K 
                (Details)                                                        
54: R43         Medical Claims and Benefits Payable - Components    HTML     40K 
                of Change in Medical Claims and Benefits Payable                 
                (Details)                                                        
55: R44         Debt - Schedule of Long-Term Debt (Details)         HTML     53K 
56: R45         Debt - Narrative (Details)                          HTML     79K 
57: R46         Stockholders' Equity - Narrative (Details)          HTML     66K 
58: R47         Stockholders' Equity - Share Activity (Details)     HTML     48K 
59: R48         Stockholders' Equity - Fair Value of Awards         HTML     28K 
                Granted and Vested (Details)                                     
60: R49         Segments - Narrative (Details)                      HTML     20K 
61: R50         Segments - Reconciliation of Gross Margin to        HTML     49K 
                Consolidated Income (Details)                                    
63: XML         IDEA XML File -- Filing Summary                      XML    112K 
11: XML         XBRL Instance -- moh-20200630_htm                    XML   2.40M 
62: EXCEL       IDEA Workbook of Financial Reports                  XLSX     83K 
 7: EX-101.CAL  XBRL Calculations -- moh-20200630_cal                XML    210K 
 8: EX-101.DEF  XBRL Definitions -- moh-20200630_def                 XML    464K 
 9: EX-101.LAB  XBRL Labels -- moh-20200630_lab                      XML   1.37M 
10: EX-101.PRE  XBRL Presentations -- moh-20200630_pre               XML    794K 
 6: EX-101.SCH  XBRL Schema -- moh-20200630                          XSD    140K 
64: JSON        XBRL Instance as JSON Data -- MetaLinks              328±   478K 
65: ZIP         XBRL Zipped Folder -- 0001179929-20-000111-xbrl      Zip    293K

‘R10’   —   Net Income per Share

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v3.20.2
Net Income per Share
 6 Months Ended
Earnings Per Share [Abstract]  
Net Income per Share Net Income per Share
The following table sets forth the calculation of net income per share:
Three Months Ended June 30,Six Months Ended June 30,
 2020201920202019
 (In millions, except net income per share)
Numerator:
Net income$276  $196  $454  $394  
Denominator:
Shares outstanding at the beginning of the period58.6  62.1  61.9  62.1  
Weighted-average number of shares issued:
Stock purchases—  —  (2.5) —  
Denominator for basic net income per share58.6  62.1  59.4  62.1  
Effect of dilutive securities: (1)
Warrants—  1.3  —  2.4  
Stock-based compensation0.8  0.6  0.8  0.6  
Denominator for diluted net income per share59.4  64.0  60.2  65.1  
Net income per share - Basic (2)
$4.72  $3.15  $7.65  $6.34  
Net income per share - Diluted (2)
$4.65  $3.06  $7.54  $6.04  
______________________________
(1) The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. All warrants outstanding as of December 31, 2019, were settled in the first quarter of 2020. For more information refer to Note 8, “Stockholders' Equity.”
(2) Source data for calculations in thousands.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed on:7/31/20
For Period end:6/30/204
12/31/1910-K
 List all Filings 
↑Top
Filing Submission 0001179929-20-000111   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 15, 8:34:11.1pm ET